The investigators retrospectively evaluated 126 consecutive treatment-naïve nAMD patients (126 eyes) who received a loading ...

Q4 2024 Earnings Call Transcript March 5, 2025 Ocugen, Inc. reports earnings inline with expectations. Reported EPS is $-0.05 EPS, expectations were $-0.05. Operator: Good morning, and welcome to ...

phases of the fluorescein angiogram in a patient with subfoveal classic choroidal neovascularization. Following one session of photodynamic therapy (top, right and bottom, left) the lesion ...

Through 2 years, the GATHER2 trial demonstrated that Izervay helped reduce the rate of GA lesion growth compared ... but the rate of choroidal neovascularization was higher in patients treated ...

endophthalmitis or choroidal neovascularization and no adverse events of special interest; considerably slower lesion growth from baseline in treated eyes versus untreated fellow eyes at 6-month ...

Professor Yit Yang discussed how pathology identified in retinal layers after an OCT scan can lead to diagnosis in his ...

Reached an alignment with FDA on Phase 2/3 pivotal confirmatory clinical trial for OCU410ST for Stargardt disease potentially expediting clinical ...

In experimental choroidal neovascularization (CNV) in rats, the PIC micelle accumulates to the CNV lesions and is retained in the lesion for as long as 168 h after intravenous administration.

A 32-year-old non-smoking woman experienced sudden blindness in one eye, which led to the discovery of metastatic lung cancer that had spread to her eyes and multiple organs.

Subjects showed considerably slower lesion growth, 44% from baseline in ... endophthalmitis or choroidal neovascularization, and no adverse events of special interest. Interim clinical data ...